TW202228671A - Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途 - Google Patents

Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途 Download PDF

Info

Publication number
TW202228671A
TW202228671A TW110143838A TW110143838A TW202228671A TW 202228671 A TW202228671 A TW 202228671A TW 110143838 A TW110143838 A TW 110143838A TW 110143838 A TW110143838 A TW 110143838A TW 202228671 A TW202228671 A TW 202228671A
Authority
TW
Taiwan
Prior art keywords
ahu377
exp3174
complex
use according
kidney disease
Prior art date
Application number
TW110143838A
Other languages
English (en)
Chinese (zh)
Inventor
孫晶超
肖瑛
景小龍
王汝歡
胡雪峰
Original Assignee
大陸商深圳信立泰藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳信立泰藥業股份有限公司 filed Critical 大陸商深圳信立泰藥業股份有限公司
Publication of TW202228671A publication Critical patent/TW202228671A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW110143838A 2020-11-25 2021-11-24 Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途 TW202228671A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011341506 2020-11-25
CN202011341506.0 2020-11-25

Publications (1)

Publication Number Publication Date
TW202228671A true TW202228671A (zh) 2022-08-01

Family

ID=81755294

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110143838A TW202228671A (zh) 2020-11-25 2021-11-24 Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途

Country Status (3)

Country Link
CN (1) CN115461052B (fr)
TW (1) TW202228671A (fr)
WO (1) WO2022111493A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118176190A (zh) * 2022-08-04 2024-06-11 深圳信立泰药业股份有限公司 ARNi化合物新晶型及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN101991597B (zh) * 2009-08-29 2012-07-04 鲁南制药集团股份有限公司 一种口服药物组合物在制备预防或治疗肾脏疾病药物中的用途
CN105367438A (zh) * 2014-08-27 2016-03-02 上海翰森生物医药科技有限公司 AHU-377α-苯乙胺盐多晶型及其制备方法和应用
WO2016029828A1 (fr) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 Acide crystallin libre, sel hemicalcique et sel d'alpha-phényléthylamine de ahu-377 et son procédé de préparation et son application
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN110801452B (zh) * 2015-03-12 2023-01-13 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
CN106390126A (zh) * 2015-07-31 2017-02-15 叶莉 含有沙坦类药物和NEPi的药物组合物
CN106466481A (zh) * 2015-08-19 2017-03-01 叶莉 沙坦类药物和NEPi复合物
AU2017209250B2 (en) * 2016-01-20 2021-07-29 Shenzhen Salubris Pharmaceuticals Co. Ltd Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof
CN114452287B (zh) * 2019-05-30 2023-05-12 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
WO2021092598A1 (fr) * 2019-11-10 2021-05-14 MyoKardia, Inc. Méthodes de traitement comprenant un modulateur de myosine

Also Published As

Publication number Publication date
CN115461052B (zh) 2023-12-22
CN115461052A (zh) 2022-12-09
WO2022111493A1 (fr) 2022-06-02

Similar Documents

Publication Publication Date Title
CN110054624B (zh) 盐酸小檗碱与咖啡酸共晶物及制备方法和其组合物与用途
TW201136945A (en) Purine nucleoside phosphoramidate
RU2600986C2 (ru) Органические аминные соли азилсартана, способ их получения и применение
CN108191913A (zh) 一种替诺福韦艾拉酚胺晶型a及其制备方法
EA012594B1 (ru) Аминокислые соли росиглитазона
TWI784276B (zh) 血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新用途
WO2015137846A1 (fr) Composés amides et procédés de leur production et utilisation
CN111635309A (zh) 一种新型解热镇痛药物及其制备方法和用途
TW202228671A (zh) Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途
WO2005121112A1 (fr) Compositions médicinales contenant de la 6-hydroxybenzbromarone ou des sels de celle-ci
TW202228677A (zh) 血管收縮素ｉｉ受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用
CN111635315A (zh) 一种解热镇痛药物及其制备方法和应用
WO2021047528A1 (fr) Maléate de dérivé d'éther d'alcool nicotinylique, forme cristalline de celui-ci et utilisation associée
WO2021052441A1 (fr) Utilisations d'un complexe constitué d'un métabolite antagoniste du récepteur de l'angiotensine ii et d'un inhibiteur de la nep dans le traitement de l'insuffisance cardiaque
CN104530176B (zh) Gaoh衍生物及其医药用途
CN111386104B (zh) 一种用于抗病毒感染的药物组合物及制备方法
RU2270708C1 (ru) Натриевая соль сополимера карбоксиметилцеллюлозы и госсипола, фармацевтическая композиция и способ профилактики или лечения вирусных заболеваний
CN110917197A (zh) 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
KR20090013736A (ko) 메트포르민 산 부가염을 포함하는 서방성 제제
WO2019242181A1 (fr) Composition pharmaceutique contenant de l'ilaprazole ou un sel de celui-ci et son procédé de préparation
CN112079835B (zh) 一种5型磷酸二酯酶抑制剂的钾盐晶型b及其制备方法和应用
CN117137913A (zh) 一种ARNi复合物与氨氯地平的复方药物组合物的新应用
CN117137921A (zh) 一种ARNi复合物的药物组合物的新应用
CN107573404B (zh) 鸟氨酸与门冬氨酸的二肽化合物的活性盐及其应用
WO2016010305A1 (fr) Nouveau sel de ténofovir disoproxil